| Identification of a primary target of thalidomide teratogenicity T Ito, H Ando, T Suzuki, T Ogura, K Hotta, Y Imamura, Y Yamaguchi, ... science 327 (5971), 1345-1350, 2010 | 2282 | 2010 |
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide AEA Lopez-Girona, D Mendy, T Ito, K Miller, AK Gandhi, J Kang, ... Leukemia 26 (11), 2326-2335, 2012 | 922 | 2012 |
| Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin … AK Gandhi, J Kang, CG Havens, T Conklin, Y Ning, L Wu, T Ito, H Ando, ... British journal of haematology 164 (6), 811-821, 2014 | 692 | 2014 |
| A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase ME Matyskiela, G Lu, T Ito, B Pagarigan, CC Lu, K Miller, W Fang, ... Nature 535 (7611), 252-257, 2016 | 592 | 2016 |
| Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs PP Chamberlain, A Lopez-Girona, K Miller, G Carmel, B Pagarigan, ... Nature structural & molecular biology 21 (9), 803-809, 2014 | 565 | 2014 |
| Teratogenic effects of thalidomide: molecular mechanisms T Ito, H Ando, H Handa Cellular and Molecular Life Sciences 68, 1569-1579, 2011 | 244 | 2011 |
| Structural basis of thalidomide enantiomer binding to cereblon T Mori, T Ito, S Liu, H Ando, S Sakamoto, Y Yamaguchi, E Tokunaga, ... Scientific reports 8 (1), 1294, 2018 | 130 | 2018 |
| p63 is a cereblon substrate involved in thalidomide teratogenicity T Asatsuma-Okumura, H Ando, M De Simone, J Yamamoto, T Sato, ... Nature chemical biology 15 (11), 1077-1084, 2019 | 128 | 2019 |
| Molecular mechanisms of thalidomide and its derivatives T Ito, H Handa Proceedings of the Japan Academy, Series B 96 (6), 189-203, 2020 | 100 | 2020 |
| Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs T Ito, H Handa International journal of hematology 104, 293-299, 2016 | 94 | 2016 |
| ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells J Yamamoto, T Suwa, Y Murase, S Tateno, H Mizutome, ... Nature chemical biology 16 (11), 1208-1217, 2020 | 82 | 2020 |
| Deciphering the mystery of thalidomide teratogenicity T Ito, H Handa Congenital anomalies 52 (1), 1-7, 2012 | 78 | 2012 |
| Molecular mechanisms of cereblon-based drugs T Asatsuma-Okumura, T Ito, H Handa Pharmacology & therapeutics 202, 132-139, 2019 | 75 | 2019 |
| Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders J Yamamoto, T Ito, Y Yamaguchi, H Handa Chemical Society Reviews 51 (15), 6234-6250, 2022 | 74 | 2022 |
| GABP, HCF‐1 and YY1 are involved in Rb gene expression during myogenesis S Deléhouzée, T Yoshikawa, C Sawa, J Sawada, T Ito, M Omori, T Wada, ... Genes to Cells 10 (7), 717-731, 2005 | 69 | 2005 |
| Molecular mechanisms of the teratogenic effects of thalidomide T Asatsuma-Okumura, T Ito, H Handa Pharmaceuticals 13 (5), 95, 2020 | 61 | 2020 |
| NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IκB-ζ degradation A Kimura, M Kitajima, K Nishida, S Serada, M Fujimoto, T Naka, ... Journal of Experimental Medicine 215 (8), 2197-2209, 2018 | 48 | 2018 |
| Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology T Ito, Y Yamaguchi, H Handa Cell Chemical Biology 28 (7), 987-999, 2021 | 43 | 2021 |
| Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound S Sakamoto, M Hatakeyama, T Ito, H Handa Bioorganic & medicinal chemistry 20 (6), 1990-2001, 2012 | 43 | 2012 |
| Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide S Tateno, M Iida, S Fujii, T Suwa, M Katayama, H Tokuyama, J Yamamoto, ... Scientific reports 10 (1), 4012, 2020 | 31 | 2020 |